NASDAQ · WGS
Healthcare · Medical - Healthcare Information Services
$94.64
Up+$1.82 (+1.92%)
Updated Sep 16, 2026, 1:39 PM
SID Score
4.9/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
WGS closed at $94.64 after 20 trading sessions, up 23.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $88.81 | $97.7299 | $88.81 | $94.64 | 833.79K |
| Sep 14, 2026 | $85.64 | $90.17 | $83.875 | $89.74 | 517.78K |
| Sep 11, 2026 | $85.17 | $87.62 | $84.355 | $85.265 | 331.6K |
| Sep 10, 2026 | $83.85 | $87.1346 | $82.00 | $83.96 | 711.68K |
| Sep 9, 2026 | $84.22 | $88.84 | $84.00 | $86.48 | 493.1K |
| Sep 8, 2026 | $85.31 | $86.57 | $83.00 | $85.87 | 426.65K |
| Sep 4, 2026 | $87.78 | $87.99 | $84.1601 | $85.99 | 304.44K |
| Sep 3, 2026 | $88.38 | $90.00 | $85.35 | $87.39 | 484.25K |
| Sep 2, 2026 | $83.94 | $87.2788 | $83.70 | $86.72 | 500.13K |
| Sep 1, 2026 | $83.84 | $85.75 | $82.79 | $84.81 | 342.09K |
| Aug 31, 2026 | $84.79 | $85.305 | $81.1901 | $84.81 | 504.19K |
| Aug 28, 2026 | $88.79 | $89.74 | $85.925 | $86.335 | 435.34K |
| Aug 27, 2026 | $90.32 | $91.78 | $88.55 | $89.24 | 354.34K |
| Aug 26, 2026 | $85.98 | $90.54 | $84.9083 | $90.285 | 430.35K |
| Aug 25, 2026 | $85.50 | $88.21 | $83.8775 | $87.405 | 682.92K |
| Aug 24, 2026 | $86.31 | $86.40 | $84.1657 | $85.19 | 504.42K |
| Aug 21, 2026 | $83.71 | $87.17 | $80.76 | $87.065 | 555.28K |
| Aug 20, 2026 | $79.295 | $84.41 | $78.80 | $82.55 | 453.35K |
| Aug 19, 2026 | $78.31 | $81.28 | $77.90 | $79.65 | 672.86K |
| Aug 18, 2026 | $76.39 | $78.60 | $75.15 | $76.34 | 389.52K |
The latest Smart Investors Daily articles mentioning WGS.
WGS research
Company profile and research snapshot.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Canaccord Genuity | Buy | — |
| Aug 4, 2026 | BTIG | Buy | — |
| Jun 29, 2026 | Guggenheim | Buy | — |
| Jun 23, 2026 | Piper Sandler | Overweight | — |
| May 5, 2026 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 9, 2026
GAITHERSBURG, Md., September 09, 2026--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
Benzinga · Sep 9, 2026
The program provides no-cost comprehensive genome sequencing for eligible pediatric patients with clinical findings, family history, or biomarker evidence suggestive of Niemann-Pick Disease Type C (NPC), helping address
Yahoo · Sep 1, 2026
GAITHERSBURG, Md., September 01, 2026--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity
Yahoo · Aug 24, 2026
A Semiconductor Packaging Company with Strong Financial Momentum and a Medical Services Company with Solid Short-Term Price Momentum.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning WGS.
